Renalytix Financials
| RNLX Stock | USD 0.16 0.01 6.67% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.51 | 0.5322 |
|
|
The essential information of the day-to-day investment outlook for Renalytix includes many different criteria found on its balance sheet. An individual investor should monitor Renalytix's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Renalytix.
Net Income |
|
Renalytix | Select Account or Indicator |
Understanding current and past Renalytix Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Renalytix's financial statements are interrelated, with each one affecting the others. For example, an increase in Renalytix's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Renalytix's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Renalytix AI. Check Renalytix's Beneish M Score to see the likelihood of Renalytix's management manipulating its earnings.
Renalytix Stock Summary
Renalytix competes with Streamline Health, HealthStream, National Research, Forian, and Mangoceuticals, Common. Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York. Renalytix operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 51 people.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US75973T1016 |
| Business Address | 1460 Broadway, New |
| Sector | Health Care Technology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | renalytix.com |
| Phone | 646 397 3970 |
| Currency | USD - US Dollar |
Renalytix Key Financial Ratios
| Return On Equity | -10.73 | ||||
| Operating Margin | (9.43) % | ||||
| Price To Sales | 9.85 X | ||||
| Revenue | 2.29 M | ||||
| Gross Profit | 720 K |
Renalytix Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 41.3M | 102.6M | 63.3M | 42.1M | 8.0M | 7.6M | |
| Net Tangible Assets | 18.8M | 71.5M | 30.6M | 7.0M | 8.0M | 7.6M | |
| Net Debt | (12.7M) | (64.8M) | (28.6M) | (12.5M) | 3.9M | 4.0M | |
| Retained Earnings | 34.9M | 3.8M | (53.0M) | (99.2M) | (211.8M) | (201.2M) | |
| Cash | 13.3M | 65.2M | 41.3M | 24.7M | 4.7M | 4.4M | |
| Net Receivables | 18K | 1.2M | 901K | 776K | 722K | 573.3K | |
| Total Liab | 5.3M | 7.5M | 20.1M | 23.7M | 15.8M | 11.5M | |
| Net Invested Capital | 36.2M | 71.5M | 42.9M | 30.4M | 35.0M | 38.4M | |
| Short Long Term Debt | 121K | 53K | 4.7M | 4.5M | 5.1M | 5.4M | |
| Total Current Assets | 18.9M | 76.0M | 47.4M | 28.3M | 6.1M | 5.8M | |
| Net Working Capital | 15.5M | 59.7M | 33.0M | 12.2M | 14.0M | 23.7M | |
| Common Stock | 192K | 233K | 241K | 299K | 478K | 265.2K | |
| Other Current Liab | 271K | 4.1M | 4.5M | 8.6M | 178K | 169.1K | |
| Accounts Payable | 2.9M | 1.8M | 2.5M | 2.9M | 2.6M | 2.5M | |
| Other Assets | 2.4M | 7.2M | 1.2M | 1.1M | 1.3M | 1.2M | |
| Inventory | 326K | 353K | 1.2M | 718K | 825.7K | 562.5K | |
| Other Current Assets | 4.3M | 1.2M | 2.3M | 1.4M | 716K | 1.3M | |
| Capital Stock | 192K | 233K | 228K | 299K | 343.9K | 247.9K |
Renalytix Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ebit | (11.1M) | (34.0M) | (53.2M) | (42.2M) | (28.9M) | (30.3M) | |
| Tax Provision | (1.4M) | (4.8M) | 25K | 2K | 4K | 4.2K | |
| Net Interest Income | 531K | (3.0M) | 9.6M | 509K | 585.4K | 556.1K | |
| Interest Income | 194K | 236K | 9.6M | 509K | 585.4K | 556.1K | |
| Gross Profit | (74K) | 687K | 918K | 701K | 156K | 148.2K | |
| Operating Income | (11.1M) | (32.6M) | (57.4M) | (42.4M) | (29.6M) | (31.1M) | |
| Research Development | 4.6M | 10.0M | 14.6M | 14.3M | 9.3M | 12.3M | |
| Ebitda | (11.6M) | (33.7M) | (52.7M) | (41.7M) | (28.5M) | (29.9M) | |
| Cost Of Revenue | 74K | 804K | 2.1M | 2.7M | 2.1M | 1.4M | |
| Income Before Tax | (10.6M) | (35.8M) | (49.6M) | (46.2M) | (33.5M) | (35.1M) | |
| Net Income | (9.3M) | (34.7M) | (45.3M) | (45.6M) | (33.5M) | (35.1M) | |
| Income Tax Expense | (1.4M) | (4.8M) | 25K | 2K | 4K | 4.2K |
Renalytix Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Renalytix AI. It measures of how well Renalytix is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Renalytix brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Renalytix had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Renalytix has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (849K) | 1M | (662K) | (370K) | (4K) | (4.2K) | |
| Change In Cash | 6.0M | 51.9M | (23.8M) | (16.7M) | (20.0M) | (19.0M) | |
| Depreciation | (485K) | 2.1M | 2.6M | 2.5M | 364K | 345.8K | |
| Capital Expenditures | 1.3M | 1.6M | 694K | 0.0 | 4K | 3.8K | |
| Net Income | (10.6M) | (35.8M) | (49.6M) | (46.2M) | (33.5M) | (35.1M) | |
| End Period Cash Flow | 13.3M | 65.2M | 41.3M | 24.7M | 4.7M | 4.4M | |
| Change To Netincome | 399K | 2.4M | (945K) | 5.3M | 4.7M | 5.7M | |
| Free Cash Flow | (11.4M) | (26.3M) | (46.4M) | (32.7M) | (30.1M) | (31.6M) | |
| Other Non Cash Items | 873K | (495K) | (5.8M) | (55K) | 3.6M | 4.5M |
Renalytix Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Renalytix's current stock value. Our valuation model uses many indicators to compare Renalytix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Renalytix competition to find correlations between indicators driving Renalytix's intrinsic value. More Info.Renalytix AI is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Renalytix's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Renalytix's earnings, one of the primary drivers of an investment's value.Renalytix AI Systematic Risk
Renalytix's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Renalytix volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Renalytix AI correlated with the market. If Beta is less than 0 Renalytix generally moves in the opposite direction as compared to the market. If Renalytix Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Renalytix AI is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Renalytix is generally in the same direction as the market. If Beta > 1 Renalytix moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Renalytix Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Renalytix's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Renalytix growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Renalytix November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Renalytix help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Renalytix AI. We use our internally-developed statistical techniques to arrive at the intrinsic value of Renalytix AI based on widely used predictive technical indicators. In general, we focus on analyzing Renalytix Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Renalytix's daily price indicators and compare them against related drivers.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 34.92 | |||
| Value At Risk | (9.52) | |||
| Potential Upside | 7.14 |
Additional Tools for Renalytix Stock Analysis
When running Renalytix's price analysis, check to measure Renalytix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Renalytix is operating at the current time. Most of Renalytix's value examination focuses on studying past and present price action to predict the probability of Renalytix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Renalytix's price. Additionally, you may evaluate how the addition of Renalytix to your portfolios can decrease your overall portfolio volatility.